Video


 
    Kazia Therapeutics Webinar - Combating Childhood Brain Cancer  
 
    Interview with Dr Matt Dun for World DIPG Awareness Day  
 
    Edison TV - Part 1 "Meet Kazia’s management team and hear about paxalisib"  
 
    Edison TV - Part 2 "Paxalisib: Beyond glioblastoma and commercial opportunities"  
 
    Edison TV - Part 3 "EVT801, capital markets and upcoming milestones"  
 
    Kazia presents at Edison Open House Global Healthcare 2022  
 
    Kazia Therapeutics AGM 2021  
 
    Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial  
 
    Ticker News hears from Dr James Garner about Kazia's EVT-801 phase 1 clinical trial  
 
    Edison TV: Kazia Therapeutics – introducing novel asset EVT-801  
 
    Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference  
 
    CEO and Managing Director, Dr James Garner, presents at ShareCafe 3 September 2021  
 
    Tickers News speaks to Kazia Therapeutics CEO James Garner About GBM Awareness Day  
 
    CEO James Garner presents at Gold Coast Investment Showcase  
 
    Edison TV: Kazia Therapeutics - overview and update with CEO James Garner  
 
    Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference  
 
    Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising  
 
    Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase  
 
    Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the Wholesale Investor Emergence event in Brisbane  
 
    Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase  
 
    Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start  
 
    NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US  
 
    CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress  
 
    CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients  
 
    Dr James Garner, CEO, speaks to Canary Networks investment forum  
 
    Sky News Interview – In-licensing of GDC-0084